FDCP
TEVA icon

Foster Dykema Cabot & Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33
Closed -$595 – 480
2024
Q3 		$595 Hold
33
– – ﹤0.01% 489
2024
Q2 		$536 Buy
+33
New +$508 ﹤0.01% 313

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Foster Dykema Cabot & Partners's TEVA Position: Q4 2024 in Review

Foster Dykema Cabot & Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 33 shares — an estimated $595 sold.

Foster Dykema Cabot & Partners first reported a position in TEVA in Q2 2024 and held it in 2 quarters. The position peaked at $595 in Q3 2024. 583 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Foster Dykema Cabot & Partners reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 33 Teva Pharmaceuticals shares in Q4 2024, an estimated $595.
  • Foster Dykema Cabot & Partners first reported a position in Teva Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Foster Dykema Cabot & Partners's Teva Pharmaceuticals position peaked at $595 in Q3 2024.
  • 583 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2024, filed 13 Feb 2025.